Ancora receives two federal grants to develop vaccine for malaria, staphylococcus aureus

Ancora Pharmaceuticals announced today that it received two federal grants under the Qualifying Therapeutic Discovery Program to continue funding its groundbreaking research and development of vaccine candidates to prevent malaria and infection by staphylococcus aureus.

“These grants will help us continue development of these ground breaking products.”

"We have the opportunity to make a tremendous global impact on the preventative standard of care for millions of individuals with our vaccine candidates," said John Pena, president of Ancora Pharmaceuticals. "These grants will help us continue development of these ground breaking products."

The National Institutes of Health grants were awarded to projects with potential to result in new therapies to treat areas of unmet medical need, prevent chronic or acute diseases or reduce the long-term growth of health care costs in the United States.

Each eligible project was awarded approximately $244,000 through the program.